Hugh Campbell
Emergency Medicine · San Antonio, TXNPI 1740244854
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 315 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Bausch Health US, LLC at 32.9% of the total. Among emergency medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$2K
- Lilly USA, LLC$836
- Novo Nordisk$387
- Pfizer$296
- GSK$295
- Amgen$251
- plus $1K from 19 others
Across 2 payments — averaging $49,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Quidel Corporation$99K
What the payments were for
- Food & beverage$4,785100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch Health US, LLC | 124 | $1,576 |
| Lilly USA, LLC | 61 | $836 |
| Novo Nordisk | 17 | $387 |
| Pfizer | 17 | $296 |
| GSK | 16 | $295 |
| Amgen | 16 | $251 |
| AstraZeneca | 9 | $220 |
| Novartis | 6 | $121 |
| Bayer | 7 | $116 |
| Abbott | 5 | $103 |
| Astellas Pharma US Inc | 5 | $88 |
| Johnson & Johnson | 6 | $75 |
| Boehringer Ingelheim | 4 | $74 |
| Idorsia Pharmaceuticals US Inc | 4 | $58 |
| IBSA Pharma Inc. | 3 | $48 |
| Upsher-smith Laboratories LLC | 3 | $47 |
| Gilead | 2 | $33 |
| Shield Therapeutics Inc | 2 | $29 |
| AbbVie(2 entities) | 2 | $26 |
| Alk-abello, Inc | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Sebela Pharmaceuticals Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,786 in reported general payments places this provider in the 95th percentile of 3,952 emergency medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 192 | $150,664 |
| TrulicityDulaglutide | 51 | $58,513 |
| OzempicSemaglutide | 57 | $55,960 |
| EliquisApixaban | 80 | $52,825 |
| RybelsusSemaglutide | 43 | $47,521 |
| MounjaroTirzepatide | 39 | $45,954 |
| XareltoRivaroxaban | 61 | $44,400 |
| MyrbetriqMirabegron | 52 | $29,126 |
| FarxigaDapagliflozin Propanediol | 46 | $28,785 |
| SynthroidLevothyroxine Sodium | 144 | $11,318 |
| Repatha SureclickEvolocumab | 19 | $10,310 |
| Dexlansoprazole DrDexlansoprazole | 48 | $10,162 |
| Repatha SyringeEvolocumab | 18 | $9,483 |
| Estradiol | 81 | $8,978 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $74 | $150,664192 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $836 | $104,46790 claims |
| Novo NordiskOzempic, Rybelsus | $387 | $103,481100 claims |
| PfizerEliquis, Premarin, Prempro | $296 | $60,713115 claims |
| Johnson & JohnsonXarelto | $75 | $44,40061 claims |
| Astellas Pharma US IncMyrbetriq | $88 | $29,12652 claims |
| AstraZenecaFarxiga | $220 | $28,78546 claims |
| AbbVieSynthroid | $26 | $11,318144 claims |
| GSKTrelegy Ellipta | $295 | $7,76712 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $86076 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,952 emergency medicine providers in Texas.
Other emergency medicine in San Antonio
- James WilliamsSan Antonio$360K
- Christine ZinkSan Antonio$27K
- Robert WigginsSan Antonio$21K
- Robert RyanSan Antonio$19K
- David MiramontesSan Antonio$11K
- Craig GoolsbySan Antonio$7K
- David StachniakSan Antonio$6K
- Gregory YuSan Antonio$6K
- John McKinneyTyler$1.9M
- William PeacockHouston$513K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.